Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
FBIO vs FBIOP: Weighing Common Stock Volatility Against Preferred Income Stability at Fortress Biotech

FBIO vs FBIOP: Weighing Common Stock Volatility Against Preferred Income Stability at Fortress Biotech

Key Takeaways

  • FBIO represents the common equity of Fortress Biotech, while FBIOP is its 9.375% Series A cumulative redeemable perpetual preferred stock — two securities with fundamentally different risk-and-return profiles tied to the same issuer.
  • FBIO has trended lower in recent months, trading near the bottom of its 52-week range amid an earnings miss and heavy reliance on non-recurring gains, while FBIOP has held comparatively steadier ground below its $25 liquidation preference.
  • Tickeron AI Verdict: FBIOP is the current favorite of the two, reflecting more consistent positioning, cumulative dividend accrual, and lower volatility relative to the common stock's downtrend.
  • FBIO carries higher upside and higher downside from commercial and pipeline catalysts, whereas FBIOP offers preferred-stock seniority and accrued income potential with limited participation in equity upside.
  • Explore more details on FBIO Major News and FBIO Today's Price Move, as well as FBIOP Major News and FBIOP Today's Price Move.
  • Discover AI-driven strategies trading these and other tickers on the Trending AI Robots page.

Introduction

Comparing FBIO and FBIOP is really a study in capital-structure positioning rather than two competing businesses. Both securities come from the same company: Fortress Biotech, Inc., a biopharmaceutical firm that acquires and advances drug candidates while holding equity stakes in its subsidiaries. FBIO is the common stock, giving exposure to the company's growth potential and volatility, while FBIOP is a fixed-rate preferred stock that prioritizes income and seniority over capital appreciation. This comparison matters for investors who are weighing growth-oriented equity risk against income-oriented preferred exposure, and for traders evaluating which instrument shows better relative market positioning right now.

FBIO Overview and Recent Performance

Fortress Biotech (FBIO) generates revenue through product sales, equity holdings, and dividend and royalty interests across its subsidiaries. Its most visible commercial driver is Emrosi, a rosacea treatment marketed by its majority-owned dermatology subsidiary Journey Medical (Nasdaq: DERM), where Fortress holds roughly a third of the shares. In its third-quarter 2026 results, Fortress reported total net revenue of about $19.2 million, up roughly 9% year over year, but below analyst expectations of approximately $22.3 million, while GAAP EPS of -$0.23 also missed consensus. A key nuance is that a large portion of recent reported profit stemmed from a one-time $205 million priority review voucher sale booked by a subsidiary, rather than recurring operations. The stock has consequently declined over recent weeks and trades near its 52-week low, with a market capitalization of roughly $65 million and year-to-date performance down approximately 45%. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

FBIOP Overview and Recent Performance

FBIOP (FBIOP) is Fortress Biotech's 9.375% Series A cumulative redeemable perpetual preferred stock, which carries a $25.00 per-share liquidation preference and a stated annual dividend of $2.34375 per share (about $0.20 monthly). Because the dividend is cumulative, any unpaid amounts continue to accrue; the company suspended regular preferred dividend payments in mid-2024, and accrued but unpaid preferred dividends have since built to roughly $16 million. The preferred shares trade below their $25 par value, a discount that reflects the suspension and the issuer's credit profile, while also offering seniority over common equity in a liquidation scenario. Recent market activity has been comparatively steadier than the common stock, reflecting FBIOP's fixed-income-like characteristics rather than the operational volatility that drives the equity.

Head-to-Head Comparison

The two instruments diverge sharply across several dimensions. In terms of capital structure, FBIOP sits senior to FBIO, holding priority over common equity in a liquidation and a cumulative dividend claim that compounds while unpaid. FBIO, by contrast, represents residual ownership and thus carries both greater upside and greater downside. On growth drivers, FBIO is tied to Emrosi prescription momentum, subsidiary financings, and pipeline licensing deals such as the recent FB-607 agreement for irritable bowel syndrome with diarrhea, while FBIOP's value hinges more on credit quality, the resumption of dividend payments, and the $25 redemption price. In recent momentum, FBIO has exhibited negative trend and elevated short interest, whereas FBIOP has been more stable. On risk factors, FBIO faces dilution, operational losses, and reliance on non-recurring gains, while FBIOP faces suspended-payment risk and interest-rate sensitivity. The key trade-off is equity upside versus preferred-income seniority. From what I see, this distinction is important because it shapes how each security responds to the same underlying company events.

Tickeron AI Verdict

Based on observable trend consistency, volatility, and relative positioning, Tickeron's AI would currently favor FBIOP over FBIO. The common stock's persistent downtrend, earnings miss, and heavy dependence on a one-time voucher sale suggest weaker near-term momentum and greater uncertainty, whereas the preferred stock's cumulative dividend accrual, seniority, and comparatively stable price action indicate more defensible positioning. This assessment is probabilistic rather than definitive: the preferred shares remain tied to the same issuer's fundamentals, and a resumption of dividends or a shift in credit outlook could alter the picture. The verdict reflects current observable conditions rather than a guarantee of future performance. I'm watching this closely as the situation evolves.

Exploring AI-Driven Trading Approaches

In my own research, I often turn to Tickeron’s AI Trading Bots to explore automated strategies for tickers like these. The platform curates a selection of AI trading bots from a broader universe of hundreds of available bots that collectively trade thousands of different tickers. Because not every bot suits every market, Tickeron highlights only those considered best aligned with current conditions. The bots on this page vary widely in trading style, strategy, timeframe, historical performance, and the specific tickers they monitor, giving traders a range of approaches rather than a single method. If you are evaluating relative performance and market positioning between securities like FBIO and FBIOP, reviewing these curated strategies may offer useful, data-driven context.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FBIO, FBIOP

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


FBIO in upward trend: price may jump up because it broke its lower Bollinger Band on November 16, 2026

FBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where FBIO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FBIO's RSI Indicator exited the oversold zone, 31 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for FBIO just turned positive on October 20, 2026. Looking at past instances where FBIO's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.

Following a +8.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where FBIO advanced for three days, in 204 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FBIO as a result. In 72 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for FBIO entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.376) is normal, around the industry mean (3.592). P/E Ratio (0.569) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.145) is also within normal values, averaging (442.120).

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. FBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel immunotherapy biologic agents

Industry Biotechnology

Industry
Biotechnology
Address
1111 Kane Concourse
Phone
+1 781 652-4500
Employees
78
Web
https://www.fortressbiotech.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.